Clinical Trial

A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma

Name: A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma — clinical trial record (NCT07120984)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: IMAGLIO

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to explore the safety and efficacy of the antibody-cytokine fusion protein L19TNF alone or in combination with alkylating chemotherapy in patients with recurrent IDH mutant glioma.

Trial Details

NCT Number	NCT07120984
Lead Sponsor	Philogen S.p.A.
Conditions	Glioma
Enrollment	52 participants
Start Date	2026-01-30
Primary Completion	2029-01-30 (estimated)
Study Completion	2029-01-30 (estimated)
Updated on ClinicalTrials.gov	2025-08-13